Record ID: MS-N069 · Family: Botanical–drug interaction / breast cancer · Clinical question: Can high-dose curcumin, with or without piperine, change tamoxifen exposure?
Evidence label: Small human pharmacokinetic study found lower tamoxifen and endoxifen exposure; recurrence and survival effects were not tested.
Evidence at a glance
- Benefit: No clinical benefit was tested.
- Certainty: Moderate for a pharmacokinetic interaction with the tested high-dose products; low for any effect on cancer outcomes.
- Risk: Endoxifen exposure fell, especially with curcumin plus piperine and among extensive CYP2D6 metabolizers.
- Cancer control: Tumor response, recurrence and survival were not measured.
What was studied
A randomized three-period crossover pharmacokinetic study enrolled 16 adults with breast cancer taking tamoxifen 20–30 mg daily. Participants received tamoxifen alone, tamoxifen with curcumin 1,200 mg three times daily, and tamoxifen with the same curcumin plus piperine 10 mg three times daily. Each phase lasted 10 or 14 days, depending on the study schedule.
The primary pharmacokinetic focus was exposure to tamoxifen and its active metabolite endoxifen over 24 hours. This was a drug-level study, not an efficacy trial.
What the results show
Compared with tamoxifen alone, endoxifen area under the concentration–time curve fell 7.7% with curcumin (95% CI −15.4% to 0.7%; P=.07) and 12.4% with curcumin plus piperine (95% CI −21.9% to −1.9%; P=.02). Effects were more pronounced in participants classified as extensive CYP2D6 metabolizers.
The authors estimated that a reduction of this size might move some people below a proposed endoxifen threshold, but that threshold-based concern is an inference. The study did not show more recurrences or worse survival.
Important limits
- Only 16 participants were studied, with short exposure phases and substantial between-person variability.
- The tested supplements were high-dose, specified products; ordinary culinary turmeric is not equivalent.
- Clinical outcomes were not assessed, and the proposed endoxifen efficacy threshold remains an indirect marker.
- Curcumin was supplied by MCO Health and piperine was a branded product; the authors reported no conflicts, and stated that funders had no role in the study.
Safety and practical context
Do not add concentrated curcumin or piperine to tamoxifen without the oncology pharmacist reviewing the exact product. Piperine can alter several drug-metabolizing enzymes and transporters. If a supplement is already being used, bring the label and dose to the care team rather than stopping prescribed tamoxifen.
Questions for the care team
- Is this turmeric used as food, or a concentrated curcumin extract?
- Does the product contain piperine/black-pepper extract or another absorption enhancer?
- Should the supplement be paused, or is drug-level monitoring appropriate in this case?
Sources checked
Last literature search: October 19, 2026 · Record appraisal: October 19, 2026
Educational information only. This record is not a prescription and does not replace advice from the oncology team or oncology pharmacist.
